Scientific Congresses in Gastroenterology

Selected Data Presentations

Select "Upcoming" to see a list of future scientific congresses in gastroenterology. Select "Past" to review data and presentations from recent congresses. This is not intended to be a comprehensive resource of all congresses and congress materials across therapeutic and disease areas.

Congress materials may include information about investigational use(s) of compounds/products that are not approved for use by the U.S. Food and Drug Administration (FDA) and/or are inconsistent with the Prescribing Information. Takeda does not recommend the use of any Takeda product beyond the approved labeling. Any decisions regarding the usage of a Takeda product beyond the approved labeling is left to the discretion of the healthcare professional. Takeda makes no representations about whether investigational compounds or unapproved uses will be approved by the FDA.

Upcoming & Past Conferences

  • Upcoming

  • Past

Advances in Inflammatory Bowel Diseases (AIBD), 2023

December 14 - 16, 2023 | Link to Event

An all-encompassing event providing real-world clinical education, case studies and new evidence-based approaches in IBD management.

American College of Gastroenterology (ACG), 2023

October 20 - 25, 2023

Premier event for clinicians and the general public about digestive disorders and the latest trends in GI technology and therapeutics.

Entyvio® (vedolizumab)

  • Response Trajectory by the Clinical Decision Support Tool Probability Groups in Vedolizumab-Treated Patients With Crohn’s Disease: A Pooled Analysis of GEMINI 2, VISIBLE 2, and VERSIFY
  • Number Needed to Treat to Maintain Clinical Remission with Advanced Therapies in Patients with Moderate to Severe Ulcerative Colitis
  • Vedolizumab Long-Term Treatment Persistence and Safety – Results From a Multinational Extended Access Program Study
  • Corticosteroid-Free Remission in Anti-TNF-Failed Crohn’s Disease Patients Treated With Vedolizumab as Second-Line Biologic Therapy: A Real-World Data Review
  • Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Bio-Naïve Patients With Late Crohn’s Disease: Results From the EVOLVE Expansion Study
  • Healthcare Resource Utilization and Costs Across Different Sequences of Advanced Therapies in Patients with Crohn’s Disease or Ulcerative Colitis

Motegrity® (prucalopride)

  • Efficacy and safety of prucalopride in patients with chronic idiopathic constipation from different racial and ethnic groups: a post hoc analysis of phase 3 and 4 clinical study data

Academy of Managed Care Pharmacy Nexus (AMCP Nexus), 2023

October 16 - 19, 2023

Annual event with more than 2,500 members and non-members of the AMCP to engage on the latest innovations and most intentional networking in managed care pharmacy.

United European Gastroenterology Week (UEGW), 2023

October 14 - 17, 2023

Global congress for researchers from around the world to present their findings on gastroenterology and digestive health.

Entyvio® (vedolizumab)

  • Machine Learning-Based Precision Medicine Approach Identifies Specific Responder Sub-Populations by Dynamic Clustering of PRO Data: Post Hoc Analysis of VARSITY Dataset
  • High-dimensional single-cell analysis identifies cellular signature associated with response to vedolizumab therapy in ulcerative colitis
  • Corticosteroid-Free Remission in Anti-TNF-Failed Crohn’s Disease Patients Treated With Vedolizumab as Second-Line Biologic Therapy: A Real-World Data Review
  • Vedolizumab Long-Term Treatment Persistence And Safety – Results From A Multinational Extended Access Programme Study

North American Society For Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN), 2023

October 4 - 7, 2023

Annual forum for participants to learn about the latest advances in pediatric gastroenterology, hepatology, and nutrition and to discuss current topics in clinical applications.

European Society for Clinical Nutrition & Metabolism Congress (ESPEN), 2023

September 11 - 14, 2023

Annual global congress dedicated to clinical nutrition and metabolism, including basic and clinical research, education, and organization of consensus statements about clinical care.

American Neurogastro­enterology and Motility Society (ANMS), 2023

August 11 - 13, 2023

Annual meeting uncovering cutting-edge research ranging from basic neurogastroenterology, translational and clinical aspects of gastrointestinal motility, and functional disorders.

Motegrity® (prucalopride)

  • Prescription medication use in chronic idiopathic constipation in the USA from the healthcare professional perspective: a retrospective observational study
  • Management of chronic idiopathic constipation in US patients from the healthcare professional perspective: a retrospective observational study

Congress of the Intestinal Rehabilitation and Transplant Association (CIRTA), 2023

June 30 - July 3, 2023

Bi-annual congress promoting intestinal rehabilitation and transplantation as a safe, innovative science involving nutritional, medical, surgical and transplant therapies through education, policy development and research.

Gattex® (teduglutide)

  • Long-term safety analysis of teduglutide treatment in adult patients with short bowel syndrome and intestinal failure (SBS-IF): analysis from a prospective, multinational registry

European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN), 2023

May 17 - 20, 2023

Annual congress discussing innovative treatments and research discoveries to enhance the standards of care for patients and help pediatric gastroenterology, hepatology, and nutrition professionals improve their practice.

Gattex® (teduglutide)

  • Pooled analysis of open-label, long-term pediatric extension studies: Safety, efficacy, and predictors of teduglutide response in patients with short bowel syndrome-associated intestinal failure

Professional Society for Health Economics and Outcomes Research (ISPOR), 2023

May 7 - 10, 2023

Leading global conference discussing how to establish, incentivize, and share value sustainable for health systems, patients, and technology developers.

Entyvio® (vedolizumab)

  • [Supplemental Material] Systematic Literature Review to Evaluate Randomized Clinical Trials of Advanced Therapies for Moderate to Severe Crohn’s Disease
  • Systematic Literature Review to Evaluate Randomized Clinical Trials of Advanced Therapies for Moderate to Severe Crohn’s Disease

Digestive Disease Week (DDW), 2023

May 6 - 9, 2023

Global meeting for physicians, researchers, and industry in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.

  • Deployment of an Artificial Intelligence Tool for Precision Medicine in Ulcerative Colitis: Preliminary Data From 8 Globally Distributed Clinical Sites

Entyvio® (vedolizumab)

  • Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naïve Patients With Crohn’s Disease: Results From the EVOLVE Expansion Study
  • Mucosal Healing With Vedolizumab in Inflammatory Bowel Disease Patients With Chronic Pouchitis: Evidence From EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial
  • Interim results from the randomized VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis
  • Change in Fatigue in Patients With Ulcerative Colitis or Crohn’s Disease Initiating Vedolizumab or Other Biologic Therapy: Data From Belgian Registry Patients
  • Disease Trajectories in Ulcerative Colitis: Early Identification of Patients With Endoscopic Remission at Week 52
  • Efficacy and Safety Outcomes in Patients With Moderate to Severe Ulcerative Colitis Stratified by Ethnicity and Race: a Pooled Analysis of Data From GEMINI 1, VARSITY, and VISIBLE 1

American Society for Parenteral and Enteral Nutrition (ASPEN), 2023

April 20 - 23, 2023

Annual global conference for interdisciplinary, clinical nutrition leaders, providing the latest in clinical nutrition research, education, and products.

Academy of Managed Care Pharmacy (AMCP), 2023

March 21 - 24, 2023

Large assembly of pharmacy and healthcare professionals dedicated to the issues of managed care pharmacy offering immersive education sessions and keynote presentations.

Motegrity® (prucalopride)

  • A real-world study of persistence and adherence to prescription medications in patients with constipation in the USA

IBDHorizons Northwest Symposium, 2023

March 11 - 11, 2023

Focused on the education related to diagnosis, management and advancement of IBD providing accredited symposia where access to IBD specialists and centers is limited.

Entyvio® (vedolizumab)

  • Dose Escalation of Biologic Therapies in Biologic Treatment-Naïve Patients with Crohn’s Disease: Results from the ODESSA-CD Study
  • Baseline Demographics and Disease Characteristics of Patients with Ulcerative Colitis Who Responded to Vedolizumab at Week 6
  • Real-World Clinical Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-Naïve Patients With Crohn’s Disease: Results From the EVOLVE Study

European Crohn's and Colitis Organization (ECCO), 2023

March 1 - 4, 2023

Global congress focused on optimizing care for patients with IBD by offering sessions around basic science, traditional medication and clinical discussions.

  • Deployment of an Artificial Intelligence Tool for Precision Medicine in Ulcerative Colitis: Preliminary Data From 8 Globally Distributed Clinical Sites
  • N15 Influence of abundant nurse staffing on patient-reported outcomes among patients with inflammatory bowel disease in clinical remission
  • Burden of Inflammatory Bowel Disease in Mexico: RISE-MX, a Multi-center, Retrospective, 3-Year Data Study

Entyvio® (vedolizumab)

  • Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Biologic-Naïve Patients With Crohn’s Disease: Results From the EVOLVE Expansion Study
  • Interim results from the randomised VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis
  • Design and rationale for the multicentre, randomised, controlled VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis
  • Change in Fatigue in Patients With Ulcerative Colitis or Crohn’s Disease Initiating Vedolizumab or Other Biologic Therapy: Data From Belgian Registry Patients
  • High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitis
  • Disease Trajectories in Ulcerative Colitis: Early Identification of Patients With Endoscopic Remission at Week 52
  • Observational Study of the Effectiveness of Vedolizumab on Treatment Outcomes and HRQoL in Biologic-Naïve Patients with Inflammatory Bowel Diseases in Greece – the TROVE Study
  • Real-world effectiveness and safety of vedolizumab induction therapy for Crohn's disease in Poland – a prospective, observational POLONEZ II study considering patient-reported outcomes
  • Efficacy and Safety Outcomes in Patients With Moderate to Severe Ulcerative Colitis Stratified by Ethnicity and Race: a Pooled Analysis of Data From GEMINI 1, VARSITY, and VISIBLE 1
  • Comparative Effectiveness and Safety of Vedolizumab vs. Anti-TNFs in Crohn's Disease Bio-Naïve Patients and Patients with Failure of One Previous Anti-TNFα (EVOLVE-IBERIA Study)
  • Real-life treatment persistence and treatment outcomes of Finnish patients with inflammatory bowel disease receiving vedolizumab as first-line biologic treatment
  • Choice of first-line biologic in moderate to severe ulcerative colitis – a decision analysis using time-on-treatment and UK costs
  • Comparative Effectiveness and Safety of Vedolizumab vs Anti-TNFs in Ulcerative Colitis Bio-Naïve Patients and Patients with Failure of One Previous Anti-TNFα (EVOLVE-IBERIA Study)
  • Clinical Trial Design in Crohn’s Disease: Interpreting Future Endpoints Based on Post Hoc Analyses of the Vedolizumab Phase 3 Trials GEMINI 2 and VISIBLE 2
  • Race and Ethnicity in Ulcerative Colitis Clinical Trial Enrollment: a Post Hoc Analysis of Patient Demographics and Clinical Characteristics From GEMINI 1, VARSITY, and VISIBLE 1

Crohn's & Colitis Congress (CCC), 2023

January 19 - 21, 2023

Annual conference for a multidisciplinary community of practitioners and researchers focusing on inflammatory bowel disease (IBD) by pairing best practices in clinical care with innovative research.

Advances in Inflammatory Bowel Diseases (AIBD), 2022

December 5 - 7, 2022

An all-encompassing event providing real-world clinical education, case studies and new evidence-based approaches in IBD management.